Sansure Biotech Inc (688289) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sansure Biotech Inc (688289) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥59.72 Million ≈ $8.74 Million USD) by net assets (CN¥7.22 Billion ≈ $1.06 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Sansure Biotech Inc to measure how many days the company can operate on defensive assets alone.
Sansure Biotech Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Sansure Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sansure Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sansure Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiajia Food Group Co Ltd
SHE:002650
|
-0.002x |
|
Huapont Life Sciences Co Ltd
SHE:002004
|
0.037x |
|
GIGAVIS LTD (PROPOSED)
KQ:420770
|
0.000x |
|
Empresa Nacional de Telecomunicaciones SA
SN:ENTEL
|
0.089x |
|
Refrigeration Electrical Engineering Corp
VN:REE
|
0.043x |
|
Hangjin Technology Co Ltd
SHE:000818
|
0.173x |
|
Sam Hwa Capaci
KO:001820
|
0.011x |
|
Diamond Power Infrastructure Limited
NSE:DIACABS
|
0.340x |
Annual Cash Flow Conversion Efficiency for Sansure Biotech Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Sansure Biotech Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Sansure Biotech Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥16.75 Billion ≈ $2.45 Billion |
CN¥183.96 Million ≈ $26.92 Million |
0.011x | -70.60% |
| 2024-12-31 | CN¥7.35 Billion ≈ $1.07 Billion |
CN¥274.45 Million ≈ $40.16 Million |
0.037x | +145.88% |
| 2023-12-31 | CN¥7.42 Billion ≈ $1.09 Billion |
CN¥112.82 Million ≈ $16.51 Million |
0.015x | -95.54% |
| 2022-12-31 | CN¥7.51 Billion ≈ $1.10 Billion |
CN¥2.56 Billion ≈ $374.45 Million |
0.341x | +15.80% |
| 2021-12-31 | CN¥6.38 Billion ≈ $933.79 Million |
CN¥1.88 Billion ≈ $274.67 Million |
0.294x | -47.17% |
| 2020-12-31 | CN¥4.75 Billion ≈ $694.40 Million |
CN¥2.64 Billion ≈ $386.65 Million |
0.557x | +1285.39% |
| 2019-12-31 | CN¥557.48 Million ≈ $81.58 Million |
CN¥22.41 Million ≈ $3.28 Million |
0.040x | +58.21% |
| 2018-12-31 | CN¥396.29 Million ≈ $57.99 Million |
CN¥10.07 Million ≈ $1.47 Million |
0.025x | +115.67% |
| 2017-12-31 | CN¥378.99 Million ≈ $55.46 Million |
CN¥-61.44 Million ≈ $-8.99 Million |
-0.162x | -- |
About Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more